ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP Annual Meeting
    • 2017 ACR/ARHP PRSYM
    • 2016-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • Register
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 0873

Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry

Philip Mease1, Robert McLean2, Taylor Blachley2, Laura Anatale-Tardiff3, Christopher Saffore4, Charlie Lovan5 and Alexis Ogdie6, 1Seattle Rheumatology Associates, P.L.L.C., Seattle, WA, 2Corrona, LLC, Waltham, MA, 3Corrona, LLC, Waltham, 4AbbVie Inc., North Chicago, IL, 5AbbVie Inc., North Chicago, 6University of Pennsylvania, Philadelphia, PA

Meeting: ACR Convergence 2020

Keywords: Outcome measures, Patient reported outcomes, Psoriatic arthritis, registry, Tumor necrosis factor (TNF)

  • Tweet
  • Email
  • Print
Save to PDF
Session Information

Date: Saturday, November 7, 2020

Session Title: Spondyloarthritis Including Psoriatic Arthritis – Treatment Poster II

Session Type: Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: When deciding to start patients with PsA on biologic therapy, rheumatologists may focus on skin involvement in addition to joint symptoms. The purpose of this study is to investigate the clinical significance of skin involvement in patients with PsA newly initiating an advanced therapy.

Methods: This was a descriptive analysis of adult patients (≥18 years) with PsA enrolled in the Corrona PsA/SpA Registry between March 2013 and March 2020. Patients were included if they initiated an advanced therapy (i.e., biologic or targeted synthetic disease-modifying antirheumatic drug) at enrollment, had a body surface area (BSA) measurement, and had no prior history of advanced therapy at initiation. Baseline demographics, clinical characteristics, treatment history, disease activity measures, and patient-reported outcome measures were stratified by BSA categories of mild (BSA ≥0 and ≤3%), moderate (BSA >3% and ≤10%), and severe (BSA >10%). Continuous measures were reported using means and standard deviation; means for BSA groups were compared using two-sample t-tests or Wilcoxon rank sum tests. Categorical measures were reported as frequencies and percentages; frequencies in BSA groups were compared using chi-square or Fisher exact tests.

Results: A total of 574 eligible initiators included 354 (61.7%), 144 (25.1%), and 76 (13.2%) with mild, moderate, and severe skin involvement, respectively. Across BSA groups, mean age was 51.0–53.2 years and 48.7–58.1% were female (Table 1). TNF inhibitors were the most commonly initiated biologic (77.1–79.0%). Overall, BSA groups were very similar across baseline demographics and comorbidities. Across BSA groups, mean baseline scores were generally similar (P>0.05) for musculoskeletal PsA domains (tender/swollen joint, dactylitis, enthesitis counts, and axial involvement), disease activity measures (Clinical Disease Activity Index, Disease Activity in Psoriatic Arthritis, and Psoriatic Arthritis Disease Activity Score), and patient-reported outcomes of pain, Health Assessment Questionnaire-Disability Index, the Assessment of SpondyloArthritis international Society Health Index, and impairment of work productivity and ability to perform daily activities (Table 2). BSA groups also did not differ significantly on prior or current therapy at baseline (Table 3).

Conclusion: The majority of patients with PsA who initiated an advanced therapy had mild to moderate skin involvement. Moreover, baseline demographics, disease activity in musculoskeletal PsA domains, and patient-reported outcomes were comparable across mild to severe skin involvement. Although rheumatologists’ treatment decisions can be driven by many factors, severe psoriasis is relatively uncommon in rheumatology practice. Thus, musculoskeletal symptoms are more likely to drive therapeutic decision making when newly initiating advanced therapies for patients with PsA.

Medical writing services provided by Joann Hettasch of JK Associates, Inc. (a Fishawack Health Company) and funded by AbbVie.


Disclosure: P. Mease, Amgen, 2, 5, 8, Bristol-Myers Squibb, 2, 5, Novartis, 2, 5, 8, Pfizer Inc, 2, 5, 8, Sun, 2, 5, UCB, 2, 5, 8, AbbVie, 2, 5, 8, Gilead, 2, 5, Janssen, 2, 5, 8, Eli Lilly, 2, 5, 8, Galapagos, 5, GlaxoSmithKline, 5; R. McLean, Corrona, 3; T. Blachley, Corrona, LLC, 3; L. Anatale-Tardiff, Corrona, 3; C. Saffore, AbbVie, 1, 3; C. Lovan, AbbVie Inc., 1, 3; A. Ogdie, Lilly, 5, Amgen, 5, AbbVie, 5, BMS, 5, Celgene, 5, Janssen, 5, Norvatis, 2, 5, Pfizer, 2, 5, Takeda, 5.

To cite this abstract in AMA style:

Mease P, McLean R, Blachley T, Anatale-Tardiff L, Saffore C, Lovan C, Ogdie A. Impact of Skin Involvement on Disease Burden Among Patients with Psoriatic Arthritis: Data from the Corrona Psoriatic Arthritis/Spondyloarthritis Registry [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/impact-of-skin-involvement-on-disease-burden-among-patients-with-psoriatic-arthritis-data-from-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/. Accessed January 22, 2021.
  • Tweet
  • Email
  • Print
Save to PDF

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/impact-of-skin-involvement-on-disease-burden-among-patients-with-psoriatic-arthritis-data-from-the-corrona-psoriatic-arthritis-spondyloarthritis-registry/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Convergence: Where Rheumatology Meets. All Virtual. November 5-9.

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2021 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.